BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Cetuximab: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Shandong Suncadia Medicine Co., Ltd., Akeso, Sanofi, Novartis Pharmaceuticals, Shanghai Institute Of Biological Products, Mirati Therapeutics Inc., Pfizer. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06915142 A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour | Advanced Malignant Tumour | recruiting | 300 |
| 2026-12 est. | P1/P2 | Akeso | NCT06943820 AK129 Combination Therapy for Advanced Solid Tumors | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal | recruiting | 230 |
| 2027-01-19 est. | P1/P2 | Sanofi SNY | NCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Solid Tumor | recruiting | 542 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-28 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-S | terminated | 74 |
| 2026-07-30 est. | P2 | Shanghai Institute Of Biological Products | NCT06194656 Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | recruiting | 81 |
| 2026-06-23 | P1/P2 | Mirati Therapeutics Inc. | NCT03785249 Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease | active not recruiting | 731 |
| 2026-06-19 | P2 | Pfizer PFE | NCT05217446 A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorecta | Metastatic Colorectal Cancer | active not recruiting | 108 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.